Landiolol: pharmacology and its use for rate control in atrial ...
Landiolol, an ultra-short acting β1-blocker, effectively reduces heart rate in atrial fibrillation without significant blood pressure drop. It shows higher cardioselectivity and potency than esmolol, with similar pharmacokinetics in Caucasian and Asian populations. Clinical trials confirm its efficacy and safety in emergency settings.
Reference News
Landiolol, an ultra-short acting β1-blocker, effectively reduces heart rate in atrial fibrillation without significant blood pressure drop. It shows higher cardioselectivity and potency than esmolol, with similar pharmacokinetics in Caucasian and Asian populations. Clinical trials confirm its efficacy and safety in emergency settings.
Landiolol, an ultra-short acting β1-blocker, effectively reduces heart rate in atrial fibrillation without significant blood pressure drop, showing high cardioselectivity and potency over esmolol. Clinical trials confirm its efficacy and safety in both Asian and Caucasian populations, with similar pharmacokinetic profiles.